Health Law Update

Home | Health Law Update

<img class="size-medium wp-image-5052 alignright" src="https://healthlawupdate.bakerhostetlerblogs.com/wp-content/uploads/sites/19/2018/04/medicare-iStock_44661964_LARGE-300x211.jpg" alt="" width="300" height="211" />

In regulations published on April 16, 2018, the Centers for Medicare &amp; Medicaid Services (CMS) issued two new documents containing guidance primarily on the Medicare Advantage (MA) program and on the Medicare prescription drug benefit program. Taken together, these two documents – a finalized regulation outlining policy changes for Contract Year 2019 (Final Rule) and a 2019 Rate Announcement and Final Call Letter (Final Call Letter) – represent further steps by the Trump administration to reduce regulatory obstacles to better healthcare delivery, to address prescription drug issues, and to improve choices available to Medicare parts C and D plan enrollees. These Final Rules, with limited exceptions, will be applicable January 1, 2019.

<a href="https://www.bakerlaw.com/alerts/cms-aims-to-decrease-burdens-and-increase-innovation-in-medicare-parts-c-and-d-with-new-april-2018-guidance">Read more &gt;&gt;&gt; </a>

CMS aims to decrease burdens and increase innovation in Medicare parts C and D with new April 2018 guidance